Peptides for Crohn's Disease and Ulcerative Colitis

Inflammatory bowel disease (IBD) encompasses Crohn's disease and ulcerative colitis — two chronic conditions characterised by inflammation of the gastrointestinal tract. The UK has one of the highest rates of IBD in the world.

UK prevalence and impact: - Approximately 500,000 people in the UK live with IBD - Crohn's disease and ulcerative colitis affect roughly equal numbers - Peak diagnosis age is 15–35, though it can develop at any age - IBD is a lifelong condition with periods of remission and flare - The UK incidence has been rising steadily, particularly for Crohn's disease

Crohn's disease: - Can affect any part of the GI tract, from mouth to anus - Most commonly affects the ileum (end of the small intestine) and colon - Inflammation is transmural (affects the full thickness of the bowel wall) - Can cause strictures, fistulas, and abscesses - Symptoms: abdominal pain, diarrhoea, weight loss, fatigue, malnutrition

Ulcerative colitis: - Affects only the colon and rectum - Inflammation is limited to the mucosal layer (inner lining) - Continuous inflammation starting from the rectum and extending proximally - Symptoms: bloody diarrhoea, urgency, abdominal pain, tenesmus

Why people with IBD explore peptides: - Current treatments do not achieve or maintain remission in all patients - Side effects of immunosuppressants and biologics can be significant - Flare frequency varies and can be frustrating despite treatment - The desire for "natural" or "healing" approaches alongside conventional medicine - BPC-157's gastric origin (it is derived from a protein in gastric juice) makes it particularly appealing to people with gut conditions

A critical note upfront: IBD is a serious, complex autoimmune condition that requires specialist medical management. Peptides should never replace prescribed IBD medications, and any changes to treatment should only be made under specialist guidance.

BPC-157 (Body Protection Compound-157) has more gut-related research than any other research peptide, which is not surprising given its origin as a synthetic fragment of a human gastric protein.

Animal studies relevant to IBD:

• •Colitis models: BPC-157 has been studied in multiple rodent models of inflammatory colitis (DSS-induced, TNBS-induced, and acetic acid-induced). These models mimic aspects of human ulcerative colitis. In most studies, BPC-157 administration reduced inflammation, promoted mucosal healing, and improved clinical scores

• •Intestinal anastomosis healing: BPC-157 accelerated healing of surgically created intestinal connections (anastomoses) in rats. This is relevant because many Crohn's patients undergo bowel resection surgery

• •Fistula healing: Limited animal data suggests BPC-157 may promote fistula healing. Fistulas are a major complication of Crohn's disease

• •Gastric ulcer healing: Multiple studies show BPC-157 accelerates gastric and duodenal ulcer healing in animal models. This was actually the earliest area of BPC-157 research

• •Short bowel adaptation: Preliminary data suggests BPC-157 may promote intestinal adaptation in short bowel models

Proposed mechanisms relevant to IBD:

1. Mucosal healing: BPC-157 appears to promote epithelial cell proliferation and migration, potentially accelerating the repair of damaged intestinal lining 2. Anti-inflammatory effects: Reduction in pro-inflammatory cytokines (TNF-alpha, IL-6) in animal colitis models 3. Angiogenesis: Promotion of blood vessel formation in damaged tissue, improving healing capacity 4. Nitric oxide system modulation: BPC-157 interacts with the NO system, which plays a key role in intestinal inflammation and healing 5. Intestinal barrier function: Some evidence suggests BPC-157 may improve tight junction integrity, which is compromised in IBD

What makes this research relevant but insufficient: The consistency of positive results across multiple animal models and research groups is noteworthy. However, IBD is far more complex than any animal model can replicate. The immune dysregulation, genetic factors, and microbiome interactions in human IBD are not adequately modelled in rodent studies.

It is essential to understand why positive animal data does not translate reliably to human benefit, particularly for a condition as complex as IBD.

Why animal IBD models are limited:

1. Model fidelity: Chemical-induced colitis in rats (DSS, TNBS) creates an acute inflammatory injury that heals when the chemical is removed. Human IBD is a chronic autoimmune condition with ongoing immune dysregulation. The models test wound healing, not IBD management

2. Immune complexity: Human IBD involves genetic susceptibility (over 200 risk loci identified), dysregulated adaptive immunity, and complex interactions with the gut microbiome. Rodent models do not replicate this complexity

3. Disease heterogeneity: IBD varies enormously between patients. What works for ileal Crohn's may be irrelevant for left-sided ulcerative colitis. Animal models test a single, uniform pathology

4. Outcome measures: Animal studies measure short-term endpoints (days to weeks). Human IBD requires sustained remission over years to decades. A peptide that accelerates acute healing may have no impact on long-term disease control

5. Drug-disease interaction: Most IBD patients take immunosuppressants, biologics, or both. The interaction between BPC-157 and these medications is entirely unknown. There is a theoretical concern that BPC-157's immune-modulating effects could interfere with biologic therapies

Historical context: Many treatments that showed dramatic efficacy in animal IBD models have failed in human trials. The track record of translation from animal models to human IBD is poor. This is not unique to peptides — it is a fundamental challenge in IBD research.

The anecdotal evidence problem: Online forums contain testimonials from IBD patients who report improvement with BPC-157. These reports are impossible to evaluate scientifically because: - IBD naturally fluctuates between flare and remission - Placebo effect is particularly strong in IBD (up to 40% placebo response in clinical trials) - People who experience no benefit or adverse effects are less likely to post - Concurrent changes in medication, diet, or stress are rarely controlled for - There is no way to verify what the person actually took or their diagnosis

Understanding what is already available through the NHS provides context for evaluating unproven peptide options.

Step-up approach (traditional):

1. 5-ASA (aminosalicylates): Mesalazine, sulfasalazine - First-line for mild-moderate ulcerative colitis - Available as oral tablets, granules, enemas, and suppositories - Generally well-tolerated

2. Corticosteroids: Prednisolone, budesonide - For acute flares; not suitable for maintenance - Significant side effects with long-term use

3. Immunomodulators: Azathioprine, mercaptopurine, methotrexate - Maintenance therapy for moderate-severe disease - Slow onset (2–3 months) - Regular blood monitoring required

4. Biologic therapies: - Anti-TNF: Infliximab (Remicade/biosimilars), adalimumab (Humira/biosimilars) - Anti-integrin: Vedolizumab (Entyvio) — gut-selective - Anti-IL12/23: Ustekinumab (Stelara) - Anti-IL23: Risankizumab (Skyrizi), guselkumab — newer options - JAK inhibitors: Tofacitinib (Xeljanz), filgotinib (Jyseleca), upadacitinib (Rinvoq) - S1P modulators: Ozanimod (Zeposia)

5. Surgery: Colectomy (ulcerative colitis) or resection (Crohn's)

The UK IBD landscape in 2026: - More biologic and small molecule options than ever before - NHS IBD services are under significant pressure but improving - IBD nurse specialists provide critical support between consultant appointments - Patient organisations (Crohn's & Colitis UK) provide excellent information and support - Clinical trials are actively recruiting across the UK through the NIHR network

The key point: The range of effective, licensed, and monitored IBD treatments available on the NHS is extensive and expanding. Patients not responding to one treatment have multiple alternative options available through their IBD specialist team.

For IBD patients interested in peptides, here is evidence-based practical guidance that prioritises safety.

What we can recommend (evidence-supported):

1. Collagen peptides (oral): May support gut lining integrity. 10–15g daily has a good safety profile. Not a treatment for IBD, but reasonable as a nutritional supplement alongside medical therapy. Discuss with your dietitian

2. Glutamine: An amino acid (not technically a peptide) with some evidence for intestinal barrier function. Commonly used by IBD dietitians at 5–15g daily. Low risk

3. Optimise nutrition: Malnutrition affects up to 75% of Crohn's patients during flares. Work with an IBD dietitian on your nutritional status

What we cannot recommend (insufficient evidence):

• •BPC-157 for IBD: Interesting animal data but no human evidence, unknown interactions with IBD medications, product quality concerns, and unknown safety in immunosuppressed patients
• •TB-500 for IBD: Even less relevant research than BPC-157 for gut conditions

Specific risks for IBD patients:

• •Immunosuppression interaction: Most IBD patients take immunosuppressive medications. BPC-157's immune-modulating effects are unpredictable and could theoretically interfere with treatment
• •Injection contamination: IBD patients on immunosuppressants are at higher risk from contaminated injectable products due to impaired immune function
• •Angiogenesis and dysplasia: Long-standing IBD increases colorectal cancer risk. BPC-157's angiogenic properties are theoretically concerning in tissue with potential dysplastic changes
• •False reassurance: The greatest risk is that peptide use provides false reassurance, leading to delayed presentation during a flare or reluctance to escalate proven medical therapy

If you are determined to try BPC-157: - Inform your IBD specialist — do not hide it from your medical team - Do not reduce or stop prescribed IBD medications - Oral formulation may be preferable to injectable for gut conditions (though oral bioavailability is uncertain) - Monitor your symptoms carefully and report any worsening - Continue all scheduled monitoring (blood tests, endoscopy)

*This article is for educational purposes only. IBD requires specialist medical management. Never change your IBD treatment without consulting your gastroenterologist or IBD nurse specialist.*